stockrowBio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO
Alert me
Bio-Rad Laboratories, Inc. (BIO) EPS (diluted)
Bio-Rad Laboratories, Inc.'s EPS (diluted) for fiscal 2025 was $27.85, compared with −$65.36 in fiscal 2024. Over the twelve months to 30 September 2026 it was $37.97. Over the past ten years it has ranged from −$121.79 (fiscal 2022) to $140.56 (fiscal 2021); the current reading is higher than 73% of that period. Bio-Rad Laboratories, Inc. ranks 1st of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $27.85 | — |
| FY2024 | −$65.36 | — |
| FY2023 | −$21.82 | — |
| FY2022 | −$121.79 | — |
| FY2021 | $140.56 | 11.38% |
| FY2020 | $126.20 | 116.58% |
| FY2019 | $58.27 | 388.02% |
| FY2018 | $11.94 | 212.57% |
| FY2017 | $3.82 | 302.11% |
| FY2016 | $0.95 | (75.32%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $17.02 | 22.89% |
| Jun 2026 | $13.85 | — |
| Mar 2026 | −$19.55 | — |
| Dec 2025 | $26.65 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BIO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement